AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9009975 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy (1 injection every morning)
Number of subjects: 153
Study 9009975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 153
Study 9009975 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 153
Study 8359954 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history
Number of subjects: 362
Study 8359954 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 362
Study 8359954 — intervention group
Group type: COMPARATOR
Intervention: Tea consumption
Number of subjects: 362
Study 8359954 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 362
Study 3526655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 56
Study 3526655 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine‐prednisone‐antilymphocyte globulin (ALG)
Number of subjects: 56
Study 31895032 — intervention group
Group type: EXPERIMENTAL
Intervention: Show-catheter (reintroduction under the CARTO 3 show-catheter image-track function)
Number of subjects: 100
Study 31895032 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy (reintroduction under conventional fluoroscopy)
Number of subjects: 100
Study 29509522 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX + lidocaine
Number of subjects: 8
Study 29509522 — intervention group
Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 8
Study 26421957 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 0
Study 26421957 — intervention group
Group type: COMPARATOR
Intervention: Reduced-GSD patch
Number of subjects: 0
Study 26421957 — intervention group
Group type: COMPARATOR
Intervention: Reduced-EE/GSD patch
Number of subjects: 0
Study 24719397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical plasma coagulation (EPC)
Number of subjects: 11
Study 24719397 — intervention group
Group type: COMPARATOR
Intervention: Potassium-titanyl-phosphate (KTP) laser photocoagulation
Number of subjects: 11
Study 23011435 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TAMAS)
Number of subjects: 30
Study 20351596 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-glycogen training
Number of subjects: 14
Study 20351596 — intervention group
Group type: COMPARATOR
Intervention: HIGH-glycogen training
Number of subjects: 14
Study 18515290 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care for older people in community hospitals
Number of subjects: 490
Study 18515290 — intervention group
Group type: COMPARATOR
Intervention: General hospital care
Number of subjects: 490
Study 15623545 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial linear cryoablation (groups U and 7)
Number of subjects: 105
Study 15623545 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) (group PV)
Number of subjects: 105
Study 15623545 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete 7 lesion (EAM validated)
Number of subjects: 105
Study 15623545 — intervention group
Group type: COMPARATOR
Intervention: Complete PVI (EAM validated)
Number of subjects: 105
Study 12895218 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (50 mg i.v.)
Number of subjects: 14
Study 12895218 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine‐N‐butyl bromide (20 mg i.v.)
Number of subjects: 14
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 micrograms/kg)
Number of subjects: 0
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ivermectin and Albendazole (400 mg)
Number of subjects: 0
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study 11127253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0
Study 11127253 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 9557072 — intervention group
Group type: COMPARATOR
Intervention: Increased urine cathepsin B activity (10.58 +/- 8.73 pmol AMC/mg creatinine/min)
Number of subjects: 0
Study 9557072 — intervention group
Group type: COMPARATOR
Intervention: Increased urine collagenase activity (8.59 +/- 4.26 pmol AMC/mg creatinine/min)
Number of subjects: 0
Study 9557072 — intervention group
Group type: COMPARATOR
Intervention: Increased urine excretion of fibronectin (214 +/- 335 ng/mg creatinine)
Number of subjects: 0
Study 9557072 — intervention group
Group type: COMPARATOR
Intervention: Increased urine excretion of TGF-beta 1 (283.55 +/- 248.13 pg/ml)
Number of subjects: 0
Study 8317720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 160
Study 8317720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 160
Study 8317720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 160
Study 8317720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 160
Study 2941573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin, an antagonist of S2-serotonergic receptors
Number of subjects: 4
Study 2941573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 28937450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session intervention (combined didactics and hands-on approach focused on technology-specific parenting)
Number of subjects: 39
Study 28937450 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 39
Study 26446770 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of ONO-5334 150 mg
Number of subjects: 14
Study 26446770 — intervention group
Group type: COMPARATOR
Intervention: Evening administration of ONO-5334 150 mg
Number of subjects: 14
Study 24395109 — intervention group
Group type: EXPERIMENTAL
Intervention: Central HER2 testing by Mayo Clinic
Number of subjects: 0
Study 24395109 — intervention group
Group type: EXPERIMENTAL
Intervention: Central ER testing by Mayo Clinic
Number of subjects: 0
Study 24395109 — intervention group
Group type: EXPERIMENTAL
Intervention: DAKO ER cocktail retesting at Mayo
Number of subjects: 0
Study 24395109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antibody ER assay
Number of subjects: 0
Study 24395109 — intervention group
Group type: COMPARATOR
Intervention: Single antibody ER assay
Number of subjects: 0
Study 23477461 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk-targeted intervention using vibration
Number of subjects: 27
Study 20579537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR) guided intervention
Number of subjects: 509
Study 20579537 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 509
Study 20579537 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR measurement
Number of subjects: 509
Study 20579537 — intervention group
Group type: COMPARATOR
Intervention: Angiographic assessment
Number of subjects: 509
Study 18258621 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry consumption
Number of subjects: 72
Study 16504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 742
Study 16504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 742
Study 16504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 742
Study 16504369 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine, Terbutaline, Salbutamol
Number of subjects: 742
Study 14519486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% nitroprusside‐based gel
Number of subjects: 20
Study 14519486 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 10958816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (specific amino acids not detailed)
Number of subjects: 0
Study 8639310 — intervention group
Group type: EXPERIMENTAL
Intervention: OND/CS
Number of subjects: 109
Study 8639310 — intervention group
Group type: COMPARATOR
Intervention: MCP/CS
Number of subjects: 109
Study 28928026 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and MS (7 module resource accessed via email over a 4 week period)
Number of subjects: 95
Study 28928026 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=50)
Number of subjects: 95
Study 27030614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 153
Study 24485216 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly intravenous zoledronate (ZOL)
Number of subjects: 110
Study 24485216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 110
Study 23554472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette gum)
Number of subjects: 18
Study 23554472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21115766 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-yogurt snack taken prior to breakfast
Number of subjects: 10
Study 21115766 — intervention group
Group type: COMPARATOR
Intervention: Breakfast taken only (control)
Number of subjects: 10
Study 18557456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-Safe 300
Number of subjects: 110
Study 18557456 — intervention group
Group type: COMPARATOR
Intervention: T380A
Number of subjects: 110
Study 16386181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) therapy
Number of subjects: 40
Study 16386181 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 40
Study 12021623 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 32
Study 12021623 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin group (n = 9 patients treated with 3‐4 mg/kg/d sodium phenytoin)
Number of subjects: 32
Study 12021623 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine group (n = 9 patients treated with 10‐20 mg/kg/d carbamazepine)
Number of subjects: 32
Study 12021623 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital group (n = 5 patients treated with 1.5‐4.5 mg/kg/d phenobarbital)
Number of subjects: 32
Study 10397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia flap technique
Number of subjects: 32
Study 10397656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fascia flap)
Number of subjects: 32
Study 8672906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 2% added to the distension medium during hysteroscopy
Number of subjects: 0
Study 8672906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ethanol monitoring
Number of subjects: 0
Study 8672906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethanol added)
Number of subjects: 0
Study 2288512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg/day
Number of subjects: 20
Study 2288512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6792916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 66
Study 6792916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30638426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (n=26)
Number of subjects: 70
Study 30638426 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (n=25)
Number of subjects: 70
Study 30638426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (n=19)
Number of subjects: 70
Study 28934784 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Injection (DI) group
Number of subjects: 36
Study 28934784 — intervention group
Group type: COMPARATOR
Intervention: Single Injection (SI) group
Number of subjects: 36
Study 25432103 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (abnormal diastolic function)
Number of subjects: 2
Study 24180167 — intervention group
Group type: COMPARATOR
Intervention: US (ultrasound guided continuous popliteal sciatic nerve block)
Number of subjects: 21
Study 24180167 — intervention group
Group type: EXPERIMENTAL
Intervention: US+NS (ultrasound guided continuous popliteal sciatic nerve block with nerve stimulation)
Number of subjects: 21
Study 24180167 — intervention group
Group type: COMPARATOR
Intervention: US only
Number of subjects: 21
Study 24180167 — intervention group
Group type: EXPERIMENTAL
Intervention: US+NS
Number of subjects: 21
Study 24180167 — intervention group
Group type: COMPARATOR
Intervention: US
Number of subjects: 21
Study 21473825 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation with synchronous intermittent mandatory ventilation and pressure support ventilation (SIMV+PSV) followed by non-invasive ventilation with PSV and PEEP after extubation.
Number of subjects: 20
Study 21473825 — intervention group
Group type: COMPARATOR
Intervention: Ordinary way of weaning from mechanical ventilation.
Number of subjects: 20
Study 18835515 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior placement of the acetabular cup
Number of subjects: 50
Study 18835515 — intervention group
Group type: COMPARATOR
Intervention: Inferior placement of the acetabular cup
Number of subjects: 50
Study 17345002 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 231
Study 17345002 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 231
Study 14687054 — intervention group
Group type: EXPERIMENTAL
Intervention: Six months cytological surveillance
Number of subjects: 476
Study 14687054 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice between six months cytological surveillance or colposcopy
Number of subjects: 476
Study 14687054 — intervention group
Group type: COMPARATOR
Intervention: No choice (six months cytological surveillance)
Number of subjects: 476
Study 11485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 0
Study 11485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 0
Study 11485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 11485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0
Study 11485146 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 9215339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Number of subjects: 6
Study 9215339 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Number of subjects: 6
Study 9215339 — intervention group
Group type: COMPARATOR
Intervention: Comparison of i.v. and SC routes
Number of subjects: 6
Study 8490373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment procedure by community psychogeriatric teams
Number of subjects: 100
Study 8490373 — intervention group
Group type: COMPARATOR
Intervention: Medical and non‐medical team members
Number of subjects: 100
Study 8490373 — intervention group
Group type: EXPERIMENTAL
Intervention: Team members with longer experience of team working
Number of subjects: 100
Study 3038428 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg tid
Number of subjects: 255
Study 3038428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg tid
Number of subjects: 255
Study 3038428 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (C + H) tid
Number of subjects: 255
Study 3038428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 30177350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Number of subjects: 91
Study 30177350 — intervention group
Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 91
Study 28464975 — intervention group
Group type: EXPERIMENTAL
Intervention: Full treatment protocol (experimental condition)
Number of subjects: 309
Study 28464975 — intervention group
Group type: COMPARATOR
Intervention: Treatment protocol without systematic exposure (control)
Number of subjects: 309
Study 26296554 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based intervention including population-based screening, centralized delivery of intervention components, involvement of primary care practitioners, and personalization of intervention components.
Number of subjects: 0
Study 26296554 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned; details on control intervention not available.
Number of subjects: 0
Study 23512283 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site evaluation of FNAB specimens
Number of subjects: 204
Study 23512283 — intervention group
Group type: COMPARATOR
Intervention: Regular cytologic examination
Number of subjects: 204
Study 21039358 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/ml bupivacaine
Number of subjects: 16
Study 21039358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/ml bupivacaine
Number of subjects: 16
Study 18495561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (1, 2 and 4 mg)
Number of subjects: 0
Study 17121050 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza Injection (SMI)
Number of subjects: 79
Study 17121050 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SI)
Number of subjects: 79
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 300 mg/m2, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 400 mg/m2, given after initial treatment in group A.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 400 mg/m2 in group B, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for both groups.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow progenitor assay pre- and post-amifostine treatment in group A.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonogenic assay in group B before AMF treatment.
Number of subjects: 27
Study 11976818 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive power of clonogenic assays for treatment response.
Number of subjects: 27
Study 10678139 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 0
Study 10678139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7549337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pallor value in ocular hypertensive patients (0.40)
Number of subjects: 33
Study 7549337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pallor value in glaucoma patients (0.50)
Number of subjects: 33
Study 7549337 — intervention group
Group type: COMPARATOR
Intervention: Mean pallor value comparison: Ocular hypertensives (0.40) vs. POAG (0.50)
Number of subjects: 33
Study 1682905 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg b.i.d. up to 10 mg b.i.d.)
Number of subjects: 40
Study 1682905 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg b.i.d. up to 160 mg b.i.d.)
Number of subjects: 40
Study 1682905 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 40
Study 1682905 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 40
Study 1682905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 6922456 — intervention group
Group type: EXPERIMENTAL
Intervention: Towel bath
Number of subjects: 105
Study 6922456 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed bath
Number of subjects: 105
Study 30907856 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized spectacles provided to children with unmet need (n = 1191)
Number of subjects: 1191
Study 30907856 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized spectacles provided to children with poor unaided vision
Number of subjects: 1191
Study 30907856 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized spectacles scheme
Number of subjects: 1191
Study 31515436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study 31515436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28505954 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative rehabilitation (8 sessions, 30 minutes each, twice weekly for 4 weeks)
Number of subjects: 21
Study 28505954 — intervention group
Group type: COMPARATOR
Intervention: Active control care
Number of subjects: 21
Study 28505954 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative rehabilitation
Number of subjects: 21
Study 26355164 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus trastuzumab
Number of subjects: 130
Study 26355164 — intervention group
Group type: COMPARATOR
Intervention: S‐1 plus cisplatin alone
Number of subjects: 130
Study 23187931 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia and intravenous sedation
Number of subjects: 20
Study 23187931 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 20
Study 21606413 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose cytarabine (12 g/m²)
Number of subjects: 933
Study 21606413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (36 g/m²)
Number of subjects: 933
Study 19564837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated subunit vaccine
Number of subjects: 658
Study 19564837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 16960527 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte solution (CES)
Number of subjects: 15
Study 16960527 — intervention group
Group type: COMPARATOR
Intervention: 2% dehydration (DEH)
Number of subjects: 15
Study 15056196 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects labeled with the same noun
Number of subjects: 123
Study 15056196 — intervention group
Group type: COMPARATOR
Intervention: Objects not labeled
Number of subjects: 123